Rose M, Fisher M
Royal North Shore Hospital of Sydney, St Leonards, NSW, Australia.
Br J Anaesth. 2001 May;86(5):678-82. doi: 10.1093/bja/86.5.678.
Patients suspected of anaphylaxis during anaesthesia have been referred to the senior author's clinic since 1974 for investigation. Since release of rocuronium on to the worldwide market, concern has been expressed about its propensity to cause anaphylaxis. We identified 24 patients who met clinical and laboratory (intradermal, mast cell tryptase and morphine radioimmunoassay) criteria for anaphylaxis to rocuronium. The incidence of rocuronium allergy in New South Wales, Australia has risen in parallel with sales, while there has been an associated fall in reactions to other neuromuscular blocking drugs. Data from intradermal testing suggested that rocuronium is intermediate in its propensity to cause allergy in known relaxant reactors compared with low-risk agents (e.g. pancuronium, vecuronium) and higher-risk agents (e.g. alcuronium, succinylcholine).
自1974年以来，怀疑在麻醉期间发生过敏反应的患者被转至资深作者的诊所进行调查。自罗库溴铵投放全球市场以来，人们一直对其引发过敏反应的倾向表示担忧。我们确定了24例符合罗库溴铵过敏反应临床和实验室（皮内试验、肥大细胞类胰蛋白酶和吗啡放射免疫测定）标准的患者。在澳大利亚新南威尔士州，罗库溴铵过敏的发生率随销量上升，而对其他神经肌肉阻滞药物的反应则相应下降。皮内试验数据表明，与低风险药物（如泮库溴铵、维库溴铵）和高风险药物（如阿库氯铵、琥珀酰胆碱）相比，罗库溴铵在已知松弛剂反应者中引发过敏的倾向处于中等水平。
